Педиатрическая фармакология (Nov 2015)

Federal Clinical Guidelines on Rendering Help to Children with Hemolytic Uremic Syndrome

  • A. N. Tsygin,
  • T. V. Vashurina,
  • T. V. Margieva,
  • P. V. Ananyin,
  • A. M. Mazo,
  • A. A. Pushkov,
  • K. V. Savostianov

DOI
https://doi.org/10.15690/pf.v12i4.1427
Journal volume & issue
Vol. 12, no. 4
pp. 447 – 455

Abstract

Read online

The hemolytic uremic syndrome (HUS) is a serious therapeutic problem in pediatrics and pediatric nephrology. HUS is one of the leading causes of acute renal failure with the potential of transforming into terminal chronic renal failure at various periods from the disease onset. The typical form of HUS with a diarrheal prodrome associated with Shiga toxin (STEC) is the most common form. Despite this fact, it requires careful confirmation of infectious etiology to exclude atypical HUS and HUS associated with pneumococcal infection in time. In respect of STEC-HUS it is recommended to conduct adequate symptomatic therapy with a timely dialysis connection if needed. The prognosis here will depend on the anuretic period duration and on the related central nervous system injuries. Atypical HUS is often based on genetic mutations leading to the complement cascade disfunction with uncontrolled activation of the alternative pathway. The overall prognosis for this prone to recurrence form is unfavourable, however, it is recommended to conduct aeculizumabum treatment which will block the terminal components of the complement cascade.

Keywords